Goodman Noah sold $570K of KYMR
Goodman Noah (Chief Business Officer) sold 5,000 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $114.00 ($109.00–$119.00, $0.57M total) across 2 trades on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the same-day open-market sale by the CBO (Goodman Noah) totaling $570k, executed under a pre-arranged 10b5-1 plan.
Market read
This is a routine insider sale disclosure; it may cause minor sentiment noise but is unlikely to drive fundamentals.
What to watch
Insider sales can still matter if unusually large relative to typical patterns, but this article provides only this single transaction size and not historical context.
Background
The article is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc.
Ticker impact
SEC Form 4 shows Kymera Therapeutics CBO Goodman Noah sold 5,000 shares on 2026-06-25 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a disclosed open-market sale by an officer with an explicit pre-arranged 10b5-1 plan, reducing interpretive value versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Because the sale is 10b5-1, it may reflect scheduled liquidity needs rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; CBO Goodman Noah sold shares on 2026-06-25.
- insiderGoodman Noah
Chief Business Officer who executed the open-market sale under a 10b5-1 plan.
